# Multimorbidity and Blood Pressure Control in Patients Attending Primary Care in Canada 

Tu N. Nguyen ${ }^{1,2(1)}$, Sumeet Kalia ${ }^{2}$, Peter Hanlon ${ }^{3}$, Bhautesh D. Jani ${ }^{3}$, Barbara I. Nicholl ${ }^{3}$, Chelsea D. Christie ${ }^{2}$, Babak Aliarzadeh ${ }^{2(0)}$, Rahim Moineddin ${ }^{2}$, Christopher Harrison', Clara Chow', Martin Fortin ${ }^{4}$, Frances S. Mair ${ }^{3}$, and Michelle Greiver ${ }^{2,5}$


#### Abstract

Background: There has been conflicting evidence on the association between multimorbidity and blood pressure (BP) control. This study aimed to investigate this associations in people with hypertension attending primary care in Canada, and to assess whether individual long-term conditions are associated with BP control. Methods: This was a cross-sectional study in people with hypertension attending primary care in Toronto between January I, 2017 and December 3I, 2019. Uncontrolled BP was defined as systolic $\mathrm{BP} \geq 140 \mathrm{mmHg}$ or diastolic $\mathrm{BP} \geq 90 \mathrm{mmHg}$. A list of II a priori selected chronic conditions was used to define multimorbidity. Multimorbidity was defined as having $\geq I$ long-term condition in addition to hypertension. Logistic regression models were used to estimate the association between multimorbidity (or individual long-term conditions) with uncontrolled BP. Results: A total of 67385 patients with hypertension were included. They had a mean age of $70,53.1 \%$ were female, $80.6 \%$ had multimorbidity, and $35.7 \%$ had uncontrolled BP. Patients with multimorbidity had lower odds of uncontrolled BP than those without multimorbidity (adjusted $\mathrm{OR}=0.72,95 \% \mathrm{Cl} 0.68$ 0.76 ). Among the long-term conditions, diabetes ( $\mathrm{aOR}=0.73,95 \% \mathrm{Cl} 0.70-0.77$ ), heart failure ( $\mathrm{aOR}=0.8 \mathrm{l}, 95 \% \mathrm{Cl} 0.73-0.9 \mathrm{I}$ ), ischemic heart disease ( $\mathrm{aOR}=0.74,95 \% \mathrm{Cl} 0.69-0.79$ ), schizophrenia ( $\mathrm{aOR}=0.79,95 \% \mathrm{Cl} 0.65-0.97$ ), depression/anxiety $(\mathrm{aOR}=0.9 \mathrm{I}, 95 \% \mathrm{Cl} 0.86-0.95)$, dementia ( $\mathrm{aOR}=0.87,95 \% \mathrm{Cl} 0.80-0.95$ ), and osteoarthritis ( $\mathrm{aOR}=0.89,95 \% \mathrm{Cl} 0.85-0.93$ ) were associated with a lower likelihood of uncontrolled BP. Conclusion: We found that multimorbidity was associated with better BP control. Several conditions were associated with better control, including diabetes, heart failure, ischemic heart disease, schizophrenia, depression/anxiety, dementia, and osteoarthritis.


## Keywords

hypertension, high blood pressure, blood pressure control, multimorbidity, primary care

Dates received: 22 September 2023; revised: 27 October 2023; accepted: I November 2023.

## Introduction

Hypertension is a risk factor for cardiovascular disease and other chronic health conditions. The prevalence of hypertension increases with age, with a prevalence of only $27 \%$ in people younger than 60 years, but $74 \%$ in people aged 80 years and older. ${ }^{1}$ Globally, blood pressure (BP) control is still suboptimal, with control rates of approximately $20 \%$ for people with hypertension. ${ }^{2}$ Poor BP control can increase the risk of heart failure, coronary heart disease, peripheral artery disease, renal failure, stroke, and dementia, and
'University of Sydney, Sydney, NSW, Australia
${ }^{2}$ University of Toronto, Toronto, ON, Canada
${ }^{3}$ University of Glasgow, Glasgow, UK
${ }^{4}$ Université de Sherbrooke, Saguenay, QC, Canada
${ }^{5}$ North York General Hospital, Toronto, ON, Canada

## Corresponding Author:

Tu N. Nguyen, Westmead Applied Research Centre, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Level 5, Block K Westmead Hospital, Hawkesbury Road, Westmead, Sydney, NSW 2145, Australia.
Email: n.nguyen@sydney.edu.au
therefore, increase the risk of developing multimorbidity in people with hypertension. ${ }^{3}$ Multimorbidity, defined as having 2 or more chronic conditions, has become a primary healthcare concern. ${ }^{4,5}$

Two out of 3 people with hypertension have additional long-term condition. ${ }^{6}$ A systematic review of 45 studies showed that the overall prevalence of multimorbidity was $66.1 \%$ (when multimorbidity was defined as having $\geq 2$ chronic conditions), and $44.2 \%$ (when multimorbidity was defined as having $\geq 3$ chronic conditions) in older adults in high-income countries. ${ }^{7}$ In the United States, 81 million adults were estimated to have multimorbidity in 2020. ${ }^{8}$ In Canada, the prevalence of multimorbidity is also high, with a reported prevalence ranging from around $30 \%$ to $70 \%$ in primary care settings, and around $17 \%$ to $59 \%$ in the general population. ${ }^{9}$ Multimorbidity increases healthcare costs and healthcare utilization including hospitalizations. ${ }^{10,11}$

Several studies have examined the impact of multimorbidity on BP control, and there has been conflicting evidence on the association between multimorbidity and hypertension control. ${ }^{12-17}$ While some studies show that the presence of multimorbidity was positively associated with BP control, ${ }^{12,13,16}$ other studies suggested that people with more comorbidities had poorer management and control of hypertension. ${ }^{15,17}$ There is minimal evidence of this association in the Canadian population. Therefore, this study aimed to investigate the association between multimorbidity and BP control in patients attending primary care in Canada, and to assess if individual comorbidities are associated with BP control.

## Methods

This study used data from the University of Toronto Practice-Based Research Network (UTOPIAN), a primary care electronic medical records (EMRs) database. The UTOPIAN database contains de-identified records from participating family medicine clinics in Ontario, Canada, with most providers practicing in the Greater Toronto Area. ${ }^{18}$ Data include de-identified patient-level information on various factors including demographics, medical diagnoses, procedures, medications, immunizations, laboratory test results, vital signs, risk factors, and clinical notes.

## Study Design and Eligible Patients

This is a cross-sectional study using the UTOPIAN 2021Q4 database with a start date of January 1,2017 and an end date of December 31, 2019. This end date was chosen to avoid the COVID-19 pandemic-related effects on the data. We identified a cohort of patients who met the following selection criteria; had hypertension before December 31, 2019; had blood pressure recorded between January 1, 2017 and December 31, 2019; and were at least 45 years old when
their blood pressure was measured. Figure 1 provides a flowchart for the cross-sectional cohort.

We defined the hypertension phenotype using the following criteria (Supplemental Appendix 2):

1. Free text documentation of hypertension was found within the (past or present) health condition section of the cumulative patient profile, including the following terms: hypertension, hypertensive, htn; OR
2. Anti-hypertensive medication was prescribed and an elevated blood pressure reading was recorded at any point in the EMR (elevated blood pressure reading is defined as systolic blood pressure $\geq 140 \mathrm{mmHg}$ or diastolic blood pressure $\geq 90 \mathrm{mmHg}$ ); OR
3. Anti-hypertensive medication was prescribed and a billing record with the diagnosis code for hypertension (ICD-9 code 401) was recorded at any point in the EMR; OR
4. A billing record with the diagnosis code for hypertension (ICD-9 code 401) and an elevated blood pressure reading was recorded at any point in the EMR (elevated blood pressure reading is defined as systolic blood pressure $\geq 140 \mathrm{mmHg}$ or diastolic blood pressure $\geq 90 \mathrm{mmHg}$ )

## Multimorbidity

Multimorbidity was defined as having 1 or more long-term conditions in addition to hypertension. This definition of multimorbidity is similar to definitions used in other studies (REFs). ${ }^{12,19,20} \mathrm{~A}$ list of 11 a priori selected chronic conditions was used to define multimorbidity, in alignment with the Centers for Disease Control and Prevention (CDC) recommendations for defining and measuring multiple chronic conditions when using Medicare claims. ${ }^{21}$ These long-term condition are: ischemic heart disease, heart failure, atrial fibrillation, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, cancers, osteoarthritis, dementia, depression and/or anxiety, and schizophrenia.

## Covariate Definitions

We used the most recent information on Body Mass Index (BMI) and smoking status as of December 31, 2019. BMI was grouped into underweight ( $\leq 18.4$ ), normal (18.5-24.9), overweight (25.0-29.9), obese class I ( $30.0-34.9$ ), obese class II ( $35.0-39.9$ ), and obese class III ( $\geq 40.0$ ). We calculated age (in years) on the date when the blood pressure measurement was recorded between January 1, 2017 and December 31, 2019. We used rurality and neighborhood income quintiles (as an indicator of socioeconomic status) using data from the 2016 Statistics Canada Census. ${ }^{22}$

We identified different classes of hypertension medication (including angiotensin converting enzyme inhibitors


Figure I. Flowchart for the generation of this cross-sectional cohort.
(ACEi), angiotensin II receptor blocker (ARBi), calcium channels, beta-blockers, diuretics, and other classes of hypertension medication) that were prescribed during the $6=$ months prior to the blood pressure measurement. The full description of drug names for each class of hypertension medication is provided in Supplemental Appendix section (i), along with the algorithm used to determine the presence of hypertension in EMRs (see Supplemental Appendix section (ii)).

## Outcome Measure

The primary outcome measurement was the most recent BP measure recorded during the study period (January 01, 2017-December 31, 2019). Uncontrolled BP was defined as having either systolic blood pressure $\geq 140 \mathrm{mmHg}$ or diastolic blood pressure $\geq 90 \mathrm{mmHg}$ for the last BP measurement prior to December 31 2019. The BP treatment
target was chosen to align with the Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension that reflected the practice during the study period. ${ }^{23}$ The SBP treatment goal is a pressure level of $<140 \mathrm{~mm} \mathrm{Hg}$ (Grade C). The DBP treatment goal is a pressure level of $<90 \mathrm{~mm} \mathrm{Hg}$ (Grade A). These targets were established using Officebased BP Measurements (OBPM). ${ }^{23}$ For patients with multiple BP readings recorded on the same day at the same visit (eg, using an automated BPtru machine), we took the average measurement of the systolic and diastolic blood pressure measures on that day.

We also conducted a sensitivity analysis, with a BP target of $<130 / 80 \mathrm{mmHg}$, as recommended by the $2018 \mathrm{ESC} /$ ESH Guidelines for the management of arterial hypertension, ${ }^{24}$ and the 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the

Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. ${ }^{25}$

## Statistical Analysis

We used descriptive statistics to summarize patient demographics and clinical characteristics associated with controlled and uncontrolled blood pressure. We used means, standard deviations, and median, minimum and maximum to summarize continuous variables, while frequencies and percentages were used to summarize categorical variables. To reduce the risk of re-identification, our reports exclude any cell count of 5 or fewer. Comparisons between patients with controlled and uncontrolled BP were assessed using Pearson's chi-square tests for categorical covariates and using 2-sample $t$-tests for continuous covariates.

We fitted logistic regression models using the Generalized Estimating Equations (GEE) with an exchangeable working correlation matrix to assess the association between multimorbidity (or individual long-term condition) on uncontrolled BP. We reported both the unadjusted odds ratios (OR) and adjusted odds ratios. To account for multicollinearity, we fitted separate logistic models using GEE for multimorbidity and different comorbidities, respectively. We a priori specified age, sex, income quintiles, smoking, and BMI as potential confounders (ie, common cause) for multimorbidity and for the outcome of BP control, while different classes of hypertension medications were considered potential mediators on the pathway between multimorbidity and BP control (see Supplemental Figure 1). In GEE models, we adjusted for the following
covariates: age, sex, income quintiles, smoking status, BMI, number of primary care visits, along with the multimorbidity status.

In a sensitivity analysis, we used a reduced threshold for blood pressure control ( $<130 / 80 \mathrm{~mm} \mathrm{Hg}$ ) and excluded BMI and smoking status in the regression models to include patients that did not have BMI or smoking status recorded.

## Ethical Approval

This study was approved by the Research Ethics Board at the University of Toronto (protocol number 00043354).

## Results

## Sample Characteristics

A total of 67385 patients who satisfied the selection criteria were included in this study. Patients in the sample had a mean age of 70.1 years $(\mathrm{SD}=11.8)$ and $53.1 \%$ were female. The prevalence of overweight and obesity was $66 \%$, with a greater proportion of patients with class II and class III obesity in the uncontrolled BP group compared to the controlled BP group. There was no difference in socioeconomic status between the 2 groups (Table 1).

## Multimorbidity

The overall prevalence of multimorbidity was $80.6 \%$. Patients with multimorbidity had a higher number of annual primary care visits than patients without multimorbidity

Table I. Patient Characteristics.

|  | Controlled BP ( $\mathrm{N}=43303$ ) | Uncontrolled BP ( $\mathrm{N}=24082$ ) | Overall ( $\mathrm{N}=67385$ ) |
| :---: | :---: | :---: | :---: |
| Age (years) |  |  |  |
| Mean (SD) | 70.3 (11.6) | 69.6 (12.2) | 70.1 (11.8) |
| Median [min, max] | 70.0 [47.0, III] | 69.0 [47.0, 110] | 70.0 [47.0, III] |
| Age group (years) |  |  |  |
| 45-74 | 30562 (70.6\%) | 17256 (71.7\%) | 47818 (71.0\%) |
| 75-84 | 8927 (20.6\%) | 4486 (18.6\%) | 13413 (19.9\%) |
| 85+ | 3814 (8.8\%) | 2340 (9.7\%) | 6154 (9.1\%) |
| Sex |  |  |  |
| Female | 22637 (52.3\%) | 13132 (54.5\%) | 35769 (53.1\%) |
| Male | 20666 (47.7\%) | 10950 (45.5\%) | 31616 (46.9\%) |
| Income quintiles |  |  |  |
| I (low income) | 8984 (20.7\%) | 5090 (21.1\%) | 14074 (20.9\%) |
| 2 | 7812 (18.0\%) | 4328 (18.0\%) | 12140 (18.0\%) |
| 3 | 7264 (16.8\%) | 3938 (16.4\%) | 11202 (16.6\%) |
| 4 | 7572 (17.5\%) | 4177 (17.3\%) | 11749 (17.4\%) |
| 5 (high income) | 10693 (24.7\%) | 5976 (24.8\%) | 16669 (24.7\%) |
| Missing | 978 (2.3\%) | 573 (2.4\%) | 1551 (2.3\%) |

Table I. (continued)

|  | Controlled BP ( $\mathrm{N}=43303$ ) | Uncontrolled BP ( $\mathrm{N}=24082$ ) | Overall ( $\mathrm{N}=67385$ ) |
| :---: | :---: | :---: | :---: |
| Multimorbidity |  |  |  |
| No | 7473 (17.3\%) | 5574 (23.1\%) | 13047 (19.4\%) |
| Yes | 35830 (82.7\%) | 18508 (76.9\%) | 54338 (80.6\%) |
| Body mass index level |  |  |  |
| Missing | 7831 (18.1\%) | 5018 (20.8\%) | 12849 (19.1\%) |
| 18.4 or less (underweight) | 267 (0.6\%) | 145 (0.6\%) | 412 (0.6\%) |
| 18.5-24.9 (normal) | 6453 (14.9\%) | 3220 (13.4\%) | 9673 (14.4\%) |
| 25-29.9 (overweight) | 13470 (31.1\%) | 6999 (29.1\%) | 20469 (30.4\%) |
| 30-34.9 (obese Class I) | 9278 (21.4\%) | 5095 (21.2\%) | 14373 (21.3\%) |
| 35-39.9 (obese Class II) | 3782 (8.7\%) | 2208 (9.2\%) | 5990 (8.9\%) |
| 40 or more (obese Class III) | 2222 (5.1\%) | 1397 (5.8\%) | 3619 (5.4\%) |
| Most recent smoking status |  |  |  |
| Missing | 11062 (25.5\%) | 6740 (28.0\%) | 17802 (26.4\%) |
| Current | 4219 (9.7\%) | 2542 (10.6\%) | 6761 (10.0\%) |
| Non-smoker | 19999 (46.2\%) | 10868 (45.1\%) | 30867 (45.8\%) |
| Past | 8023 (18.5\%) | 3932 (16.3\%) | 11955 (17.7\%) |
| Cancer |  |  |  |
| No | 37881 (87.5\%) | 21349 (88.7\%) | 59230 (87.9\%) |
| Yes | 5422 (12.5\%) | 2733 (11.3\%) | 8155 (I2.1\%) |
| Ischemic heart disease |  |  |  |
| No | 37182 (85.9\%) | 21679 (90.0\%) | 58861 (87.4\%) |
| Yes | 6121 (14.1\%) | 2403 (10.0\%) | 8524 (12.6\%) |
| Heart failure |  |  |  |
| No | 40754 (94.1\%) | 23082 (95.8\%) | 63836 (94.7\%) |
| Yes | 2549 (5.9\%) | 1000 (4.2\%) | 3549 (5.3\%) |
| Atrial fibrillation |  |  |  |
| No | 38362 (88.6\%) | 21878 (90.8\%) | 60240 (89.4\%) |
| Yes | 494 ( $11.4 \%$ ) | 2204 (9.2\%) | 7145 (10.6\%) |
| Diabetes mellitus |  |  |  |
| No | 28126 (65.0\%) | 17210 (71.5\%) | 45336 (67.3\%) |
| Yes | 15177 (35.0\%) | 6872 (28.5\%) | 22049 (32.7\%) |
| Chronic kidney disease |  |  |  |
| No | 35292 (81.5\%) | 20021 (83.1\%) | 55313 (82.1\%) |
| Yes | 8011 (18.5\%) | 4061 (16.9\%) | 12072 (17.9\%) |
| Chronic obstructive pulmonary disease |  |  |  |
| No | 39365 (90.9\%) | 22197 (92.2\%) | 61562 (91.4\%) |
| Yes | 3938 (9.1\%) | 1885 (7.8\%) | 5823 (8.6\%) |
| Osteoarthritis |  |  |  |
| No | 26654 (61.6\%) | 15500 (64.4\%) | 42 154 (62.6\%) |
| Yes | 16649 (38.4\%) | 8582 (35.6\%) | 25231 (37.4\%) |
| Dementia |  |  |  |
| No | 39774 (91.9\%) | 22422 (93.1\%) | 62196 (92.3\%) |
| Yes | 3529 (8.1\%) | 1660 (6.9\%) | 5189 (7.7\%) |
| Depression and/or anxiety |  |  |  |
| No | 28943 (66.8\%) | 16728 (69.5\%) | 45671 (67.8\%) |
| Yes | 14360 (33.2\%) | 7354 (30.5\%) | 21714 (32.2\%) |
| Schizophrenia |  |  |  |
| No | 42726 (98.7\%) | 23853 (99.0\%) | 66579 (98.8\%) |
| Yes | 577 (1.3\%) | 229 (1.0\%) | 806 (1.2\%) |

Comparisons between patients with controlled and uncontrolled BP were assessed using Pearson's chi-square tests for categorical covariates and
2 -sample $t$-tests for continuous covariates. All $P<.00 \mathrm{I}$.
in 2017, 2018, and 2019 (Supplemental Table 2). As an example, $8.0 \%$ of the patients with multimorbidity had more than 9 visits in 2019 compared to $1.9 \%$ of patients without multimorbidity

## Uncontrolled Blood Pressure

Overall, $35.7 \%$ of patients had uncontrolled BP ( $34.1 \%$ in patients with multimorbidity and $42.7 \%$ in patients without multimorbidity, $P<.001$ ). Figure 2 presents the percentages of uncontrolled BP in patients with and without multimorbidity. Across the 3 age groups, patients with multimorbidity had lower rates of uncontrolled BP compared to patients without multimorbidity.

## The Association Between Multimorbidity and Hypertension Control

Patients with multimorbidity had lower odds of uncontrolled BP compared to those without multimorbidity (adjusted $\mathrm{OR}=0.72,95 \%$ CI $0.68-0.76$, adjusted for age, sex, income quintiles, smoking status, body mass index, and number of visits). Younger patients had lower odds of
having uncontrolled BP than older patients. Obese patients (in class I, II, and III) had higher odds of uncontrolled BP than those with normal BMI. Current smokers had higher odds of having uncontrolled BP compared to non-smokers. Increasing number of visits to primary care doctors was associated with lower odds of uncontrolled BP (Figure 3).


Figure 2. Percentage of patients with uncontrolled blood pressure.


Figure 3. Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to patient characteristics.
*Odds ratio >I means a greater likelihood of uncontrolled blood pressure. Models were adjusted for age, sex, income quintiles, smoking status, body mass index, and number of visits.


Figure 4. Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to individual long-term conditions. *Odds ratio > I means a greater likelihood of uncontrolled blood pressure. Models were adjusted for age, sex, income quintiles, smoking status, body mass index, and number of visits.

## The Association Between Types of Long-Term Conditions and Hypertension Control

Among the long-term conditions, 7 conditions were significantly associated with lower likelihood of uncontrolled BP: diabetes (adjusted OR $=0.73,95 \%$ CI $0.70-0.77$ ), heart failure (adjusted $\mathrm{OR}=0.81,95 \% \mathrm{CI} 0.73-0.91$ ), ischemic heart disease (adjusted OR=0.74, 95\%CI 0.69-0.79), schizophrenia (adjusted OR=0.79, 95\%CI 0.65-0.97), depression/anxiety (adjusted OR=0.91, 95\%CI 0.86-0.95), dementia (adjusted $\mathrm{OR}=0.87,95 \% \mathrm{CI} 0.80-0.95$ ), and osteoarthritis (adjusted OR $=0.89,95 \%$ CI $0.85-0.93$ ). The remaining long-term conditions (atrial fibrillation, chronic obstructive pulmonary disease, chronic kidney disease, and cancer) were not associated with uncontrolled BP (Figure 4).

## Sensitivity Analysis

Sensitivity analyses showed consistent results (Supplemental Tables 3 and 4).

In GEE models using $\geq 130 / 80 \mathrm{mmHg}$ as the threshold for sub-optimal blood pressure control, multimorbidity was still significantly associated with reduced likelihoods of uncontrolled BP (adjusted ORs 0.56, 95\%CI 0.54-0.59), adjusting for age, sex, income quintiles, body mass index, and number of visits.

## Discussion

Our analysis in 67385 Canadians aged 45 years or more with hypertension attending primary care from 2017 to 2019 showed that multimorbidity was associated with approximately $30 \%$ lower odds of uncontrolled BP. The individual long-term conditions that were significantly associated with lower likelihood of uncontrolled BP include
diabetes, heart failure, ischemic heart disease, schizophrenia, depression/anxiety, dementia, or osteoarthritis.

Our finding aligns with other studies that examined this association, which reported that multimorbidity was one of the strongest predictors of controlled BP in patients with hypertension. Tapela et $\mathrm{al}^{26}$ found that multimorbidity was positively associated with BP control among participants with hypertension in the UK Biobank, and the types of comorbidities that were significantly associated with controlled BP included cardiovascular disease ( $\mathrm{OR}=2.11$, $95 \%$ CI $2.04-2.19)$, diabetes $(\mathrm{OR}=1.32,95 \%$ CI 1.27-1.36), migraines $(\mathrm{OR}=1.68,95 \% \mathrm{CI} 1.56-1.81)$, and depression $(\mathrm{OR}=1.27,95 \% \mathrm{CI} 1.20-1.34)$. Another study conducted by Sarkar et al ${ }^{12}$ in 31676 patients with hypertension in primary care in the UK, found that 16140 (51 \%) had multimorbidity, and hypertensive patients with multimorbidity had lower BP than those with hypertension alone. Mini et $\mathrm{al}^{16}$ also reported that blood pressure control was better in participants who reported any comorbidity ( $O R=2.37$, 95\%CI 1.51-3.71) compared to those who did not report any. However, several other studies reported the opposite findings-people with more comorbidities had poorer management and control of hypertension. In a study of 223286 patients with hypertension in Hongkong, Wong et al ${ }^{15}$ found that the proportion of patients having poor BP control increased from $35.0 \%$ to $65.0 \%$ and $69.1 \%$ when the number of medical conditions increased from 0 to 1 and 2 , respectively. However, this study enrolled adult patients prescribed their first antihypertensive agents; hence people with comorbidities (such as diabetes, heart failure, and coronary heart disease) who were already on a relevant medication (beta-blockers, ACE inhibitors) for these reasons would be excluded from the hypertension cohort. A crosssectional analysis of the World Health Organization Study of Global Ageing and Adult Health (WHO SAGE) Wave 1 (2007-2010) in 41557 adults (9778 with hypertension)
from 6 middle-income countries (including China, Ghana, India, Mexico, Russia, and South Africa) reported that more comorbidities were associated with increased odds of uncontrolled hypertension. ${ }^{17}$

A possible explanation that would account for the lower odds of uncontrolled hypertension in patients with chronic conditions like diabetes, heart failure, ischemic heart disease, schizophrenia, depression/anxiety, or osteoarthritis may be explained by the fact that patients with these conditions tend to have frequent doctor visits. As with dementia, some studies showed that dementia was associated with lower blood pressure. ${ }^{27,28}$

The results from this study may reflect the achievement of primary care in controlling cardiovascular risk factors in patients with multimorbidity, including regular BP measures and treatment. Comorbidities may be associated with more frequent healthcare utilization and hence increase the monitoring of chronic conditions, including BP measurement and counselling on lifestyle modifications and medication adherence. Another explanation could be the study's participation selection processes. Among people with hypertension as their only chronic health condition, those with poorer BP control may be more motivated to attend primary care and hence were included in this cohort. Thus, the observed associations could be explained by selection bias-hypertensive patients with no comorbidities, but uncontrolled BP may have been more likely to seek primary care compared to hypertensive patients with no comorbidities and controlled BP. These lead to opportunities to measure BP and obtain scripts, reminders given to them on taking medications, and better lifestyle modifications.

## Strengths

This study has several strengths. To the best of our knowledge, it is the first study reporting the association between multimorbidity and blood pressure control in Canada. The study is based on detailed clinical data. It is grounded in real world data from routine primary care practices. The large sample size of this study provides sufficient statistical power, allowing for point estimates with precise confidence intervals.

## Limitations

The study data was only collected from patients in Ontario and is not nationally representative. We might be unable to capture all cases of hypertension and/or prescriptions of anti-hypertensive medications in the EMR data. Duration and severity of hypertension, and lifestyle modification, an essential strategy in the management of hypertension and can influence BP control, could not be captured through the EMR data. In addition, BP control was defined based on BP measurement at the clinics, which may be influenced by the
white coat effect. Therefore, results should be replicated and cautiously interpreted before generalizing to all patients in primary care.

## Conclusion

In this large-scale study of patients attending primary care with hypertension, multimorbidity was associated with better BP control. Several long-term conditions were associated with better control, including diabetes, heart failure, ischemic heart disease, schizophrenia, depression/anxiety, dementia, and osteoarthritis. Further large-scale studies are needed to explore the mechanisms underlying the associations between multimorbidity and BP control, and to understand barriers to BP control in primary care.

## Acknowledgments

Dr Tu Nguyen is supported by the University of Sydney - Global Development Awards.
Dr. Greiver was supported through the Gordon F. Cheesbrough Research Chair in Family and Community Medicine from North York General Hospital.
We are grateful to the patients and physicians who allowed their data to be shared to make this project possible.

## Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## ORCID iDs

Tu N. Nguyen (iD https://orcid.org/0000-0002-8836-8920
Babak Aliarzadeh (iD https://orcid.org/0000-0002-3185-9307

## Supplemental Material

Supplemental material for this article is available online.

## References

1. Oliveros E, Patel H, Kyung S, et al. Hypertension in older adults: assessment, management, and challenges. Clin Cardiol. 2019;43:99-107.
2. Nguyen TN, Chow CK. Global and national high blood pressure burden and control. Lancet. 2021;398(10304):932-933.
3. Sierra C. Hypertension and the risk of Dementia. Front Cardiovasc Med 2020;7:5.
4. Fortin M, Dubois MF, Hudon C, Soubhi H, Almirall J. Multimorbidity and quality of life: a closer look. Health Qual Life Outcomes. 2007;5:52.
5. Skou ST, Mair FS, Fortin M, et al. Multimorbidity. Nat Rev Dis Primers. 2022;8(1):48.
6. Kennard L, O'Shaughnessy KM. Treating hypertension in patients with medical comorbidities. BMJ. 2016;352:1101.
7. Ofori-Asenso R, Chin KL, Curtis AJ, Zomer E, Zoungas S, Liew D. Recent patterns of multimorbidity among older adults in high-income countries. Popul Health Manag. 2019; 22(2):127-137.
8. Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med. 2007; 22 Suppl 3:391-395.
9. Mokraoui NM, Haggerty J, Almirall J, Fortin M. Prevalence of self-reported multimorbidity in the general population and in primary care practices: a cross-sectional study. BMC Res Notes. 2016;9:314.
10. Marina S-B, Mark A, Alessandra B, et al. Impact of multimorbidity on healthcare costs and utilisation: a systematic review of the UK literature. Br J Gen Pract. 2021; 71(702):e39.
11. Rodrigues LP, de Oliveira Rezende AT, Delpino FM, et al. Association between multimorbidity and hospitalization in older adults: systematic review and meta-analysis. Age Ageing. 2022;51(7):afac 155.
12. Sarkar C, Dodhia H, Crompton J, et al. Hypertension: a crosssectional study of the role of multimorbidity in blood pressure control. BMC Fam Pract. 2015;16:98.
13. Paulsen MS, Andersen M, Thomsen JL, et al. Multimorbidity and blood pressure control in 37651 hypertensive patients from danish general practice. J Am Heart Assoc. 2012;2(1): e004531.
14. Tran J, Norton R, Canoy D, et al. Multi-morbidity and blood pressure trajectories in hypertensive patients: a multiple landmark cohort study. PLoS Med. 2021;18(6):e1003674.
15. Wong MC, Wang HH, Cheung CS, et al. Factors associated with multimorbidity and its link with poor blood pressure control among 223,286 hypertensive patients. Int J Cardiol. 2014;177(1):202-208.
16. Mini G, Mohan M, Sarma P, Thankappan K. Multi-morbidity and blood pressure control: results of a cross-sectional study among school teachers in Kerala, India. Indian J Public Health. 2021;65(2):190-193.
17. Sum G, Koh GC-H, Mercer SW, et al. Patients with more comorbidities have better detection of chronic conditions, but poorer management and control: findings from six middleincome countries. BMC Public Health. 2020;20(1):9.
18. Tu K, Sodhi S, Kidd M, et al. The University of Toronto Family Medicine Report: Caring for our Diverse Populations. Toronto: Department of Family and Community Medicine, University of Toronto, 2020.
19. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. Ann Fam Med 2012; 10(2):142-151.
20. Kone AP, Mondor L, Maxwell C, Kabir US, Rosella LC, Wodchis WP. Rising burden of multimorbidity and related socio-demographic factors: a repeated cross-sectional study of Ontarians. Can J Public Health. 2021;112(4):737-747.
21. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic conditions: imperatives for research, policy, program, and practice. Prev Chronic Dis. 2013;10:E66
22. Statistics Canada. Postal CodeOM Conversion File (PCCF), Reference Guide 2017. 2017, Accessed November 1, 2022. https://www150.statcan.gc.ca/n1/pub/92-154-g/92-154-g20 17001-eng.htm
23. Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32(5):569-588.
24. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.
25. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018; 71(6):e13-e115.
26. Tapela N, Collister J, Clifton L, Turnbull I, Rahimi K, Hunter DJ. Prevalence and determinants of hypertension control among almost 100000 treated adults in the UK. Open Heart. 2021;8(1): 0001461.
27. Moretti R, Torre P, Antonello RM, Manganaro D, Vilotti C, Pizzolato G. Risk factors for vascular dementia: hypotension as a key point. Vasc Health Risk Manag. 2008;4(2):395-402.
28. Molander L, Gustafson Y, Lövheim H. Low Blood pressure is associated with cognitive impairment in very old people. Dementia Geriatr Cogn Disord. 2010;29(4):335-341.
